Cargando…
Management of Hepple Stage V Osteochondral Lesion of the Talus with a Platelet-Rich Plasma Scaffold
There has been no consensus on the treatment or prognosis of Hepple stage V osteochondral lesions of the talus (OLTs), especially for lesions greater than 1.5 cm(2) in size. The objective of this study was to investigate the clinical outcomes achieved upon application of a platelet-rich plasma (PRP)...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5376404/ https://www.ncbi.nlm.nih.gov/pubmed/28401159 http://dx.doi.org/10.1155/2017/6525373 |
_version_ | 1782519150690697216 |
---|---|
author | Gu, Wenqi Li, Tanzhu Shi, Zhongmin Mei, Guohua Xue, Jianfeng Zou, Jian Wang, Xiaokang Zhang, Haotong Xu, Hongwei |
author_facet | Gu, Wenqi Li, Tanzhu Shi, Zhongmin Mei, Guohua Xue, Jianfeng Zou, Jian Wang, Xiaokang Zhang, Haotong Xu, Hongwei |
author_sort | Gu, Wenqi |
collection | PubMed |
description | There has been no consensus on the treatment or prognosis of Hepple stage V osteochondral lesions of the talus (OLTs), especially for lesions greater than 1.5 cm(2) in size. The objective of this study was to investigate the clinical outcomes achieved upon application of a platelet-rich plasma (PRP) scaffold with a cancellous bone autograft for Hepple stage V OLTs. Fourteen patients (mean age, 39 years) were treated with a cancellous bone graft and a PRP scaffold between 2013 and 2015. The mean time to surgical treatment was 23.5 months. Ankle X-ray and magnetic resonance imaging were performed at the final follow-up. Functional outcomes were evaluated according to the Visual Analog Scale (VAS) score, American Orthopaedic Foot and Ankle Society (AOFAS) score, and Short Form 36 (SF-36) score. The range of motion (ROM) of the ankle joint and complications also were recorded. Thirteen patients completed the full follow-up, with a mean follow-up duration of 18 months. MRI demonstrated the complete regeneration of subchondral bone and cartilage in all patients. The postoperative VAS, AOFAS ankle and hindfoot, and SF-36 scores were improved significantly (all P < 0.001) without obvious complications. We suggest that, for the Hepple stage V OLTs, management with cancellous bone graft and PRP scaffold may be a safe and effective treatment. |
format | Online Article Text |
id | pubmed-5376404 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-53764042017-04-11 Management of Hepple Stage V Osteochondral Lesion of the Talus with a Platelet-Rich Plasma Scaffold Gu, Wenqi Li, Tanzhu Shi, Zhongmin Mei, Guohua Xue, Jianfeng Zou, Jian Wang, Xiaokang Zhang, Haotong Xu, Hongwei Biomed Res Int Clinical Study There has been no consensus on the treatment or prognosis of Hepple stage V osteochondral lesions of the talus (OLTs), especially for lesions greater than 1.5 cm(2) in size. The objective of this study was to investigate the clinical outcomes achieved upon application of a platelet-rich plasma (PRP) scaffold with a cancellous bone autograft for Hepple stage V OLTs. Fourteen patients (mean age, 39 years) were treated with a cancellous bone graft and a PRP scaffold between 2013 and 2015. The mean time to surgical treatment was 23.5 months. Ankle X-ray and magnetic resonance imaging were performed at the final follow-up. Functional outcomes were evaluated according to the Visual Analog Scale (VAS) score, American Orthopaedic Foot and Ankle Society (AOFAS) score, and Short Form 36 (SF-36) score. The range of motion (ROM) of the ankle joint and complications also were recorded. Thirteen patients completed the full follow-up, with a mean follow-up duration of 18 months. MRI demonstrated the complete regeneration of subchondral bone and cartilage in all patients. The postoperative VAS, AOFAS ankle and hindfoot, and SF-36 scores were improved significantly (all P < 0.001) without obvious complications. We suggest that, for the Hepple stage V OLTs, management with cancellous bone graft and PRP scaffold may be a safe and effective treatment. Hindawi 2017 2017-03-16 /pmc/articles/PMC5376404/ /pubmed/28401159 http://dx.doi.org/10.1155/2017/6525373 Text en Copyright © 2017 Wenqi Gu et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Gu, Wenqi Li, Tanzhu Shi, Zhongmin Mei, Guohua Xue, Jianfeng Zou, Jian Wang, Xiaokang Zhang, Haotong Xu, Hongwei Management of Hepple Stage V Osteochondral Lesion of the Talus with a Platelet-Rich Plasma Scaffold |
title | Management of Hepple Stage V Osteochondral Lesion of the Talus with a Platelet-Rich Plasma Scaffold |
title_full | Management of Hepple Stage V Osteochondral Lesion of the Talus with a Platelet-Rich Plasma Scaffold |
title_fullStr | Management of Hepple Stage V Osteochondral Lesion of the Talus with a Platelet-Rich Plasma Scaffold |
title_full_unstemmed | Management of Hepple Stage V Osteochondral Lesion of the Talus with a Platelet-Rich Plasma Scaffold |
title_short | Management of Hepple Stage V Osteochondral Lesion of the Talus with a Platelet-Rich Plasma Scaffold |
title_sort | management of hepple stage v osteochondral lesion of the talus with a platelet-rich plasma scaffold |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5376404/ https://www.ncbi.nlm.nih.gov/pubmed/28401159 http://dx.doi.org/10.1155/2017/6525373 |
work_keys_str_mv | AT guwenqi managementofhepplestagevosteochondrallesionofthetaluswithaplateletrichplasmascaffold AT litanzhu managementofhepplestagevosteochondrallesionofthetaluswithaplateletrichplasmascaffold AT shizhongmin managementofhepplestagevosteochondrallesionofthetaluswithaplateletrichplasmascaffold AT meiguohua managementofhepplestagevosteochondrallesionofthetaluswithaplateletrichplasmascaffold AT xuejianfeng managementofhepplestagevosteochondrallesionofthetaluswithaplateletrichplasmascaffold AT zoujian managementofhepplestagevosteochondrallesionofthetaluswithaplateletrichplasmascaffold AT wangxiaokang managementofhepplestagevosteochondrallesionofthetaluswithaplateletrichplasmascaffold AT zhanghaotong managementofhepplestagevosteochondrallesionofthetaluswithaplateletrichplasmascaffold AT xuhongwei managementofhepplestagevosteochondrallesionofthetaluswithaplateletrichplasmascaffold |